Showing results (241-250 of 592) with videos related to
Sort By:
Pageof 60
Clinical Lung Cancer|March 4, 2025
Supraclavicular Lymph Node Metastases in Advanced Lung Cancer: Prevalence and Analysis of Demographic, Clinical and Molecular CharacteristicsRocco Trisolini, Valeria Cetoretta, Giovanni Sotgiu, et al.Cancers|May 14, 2020
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future PerspectivesMiriam Grazia Ferrara, Vincenzo Di Noia, Ettore D'Argento, et al.Critical Reviews in Oncology/Hematology|December 17, 2013
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trialsSara Pilotto, Massimo Di Maio, Umberto Peretti, et al.Cancer|June 20, 2007
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trialsEmilio Bria, Michele Milella, Alain Gelibter, et al.Anti-Cancer Drugs|December 13, 2006
Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patientsCecilia Nisticò, Emilio Bria, Federica Cuppone, et al.The Oncologist|May 31, 2022
Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With OutcomeAlberto Pavan, Alessandra Ferro, Francesco Fortarezza, et al.Biomed Research International|April 23, 2013
Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual bloodFilippo Rossignoli, Anna Caselli, Giulia Grisendi, et al.Journal of Neuro-Oncology|March 1, 2018
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancerAmélie Darlix, Gaia Griguolo, Simon Thezenas, et al.European Journal of Cancer (Oxford, England : 1990)|March 9, 2023
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerMark E Robson, Seock-Ah Im, Elzbieta Senkus, et al.Seminars in Oncology|October 2, 2022
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysisLorenzo Belluomini, Sara Pilotto, Alice Avancini, et al.Pageof 60